400 related articles for article (PubMed ID: 22593494)
1. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
Zugor V; Witt JH; Heidenreich A; Porres D; Labanaris AP
Anticancer Res; 2012 May; 32(5):2091-5. PubMed ID: 22593494
[TBL] [Abstract][Full Text] [Related]
2. Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
Zugor V; Labanaris AP; Bauer RM; Witt JH
Anticancer Res; 2012 May; 32(5):2079-83. PubMed ID: 22593492
[TBL] [Abstract][Full Text] [Related]
3. Robotic-assisted radical prostatectomy in men ≤50 years of age. Surgical, oncological and functional outcomes.
Labanaris AP; Zugor V; Witt JH
Anticancer Res; 2012 May; 32(5):2097-101. PubMed ID: 22593495
[TBL] [Abstract][Full Text] [Related]
4. Robotic-assisted radical prostatectomy in men ≥75 years of age. Surgical, oncological and functional outcomes.
Labanaris AP; Witt JH; Zugor V
Anticancer Res; 2012 May; 32(5):2085-9. PubMed ID: 22593493
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
7. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
[TBL] [Abstract][Full Text] [Related]
12. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
13. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
14. Robot assisted radical prostatectomy for elderly patients with high risk prostate cancer.
Rogers CG; Sammon JD; Sukumar S; Diaz M; Peabody J; Menon M
Urol Oncol; 2013 Feb; 31(2):193-7. PubMed ID: 21803614
[TBL] [Abstract][Full Text] [Related]
15. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
16. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
18. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
[TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.
Krambeck AE; DiMarco DS; Rangel LJ; Bergstralh EJ; Myers RP; Blute ML; Gettman MT
BJU Int; 2009 Feb; 103(4):448-53. PubMed ID: 18778350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]